Alcon Acquires EYSUVIS and INVELTYS Commercial Portfolio from Kala Pharmaceuticals
May 23, 2022
Alcon Inc. agreed to acquire the commercial portfolio and related intellectual property for EYSUVIS and INVELTYS from Kala Pharmaceuticals for an upfront payment of $60 million, with Kala eligible for future commercial milestone payments. The asset sale allows Alcon to expand its ophthalmic drug franchises while enabling Kala to focus on its pipeline (KPI-012) and extend its cash runway.
- Buyers
- Alcon Inc.
- Targets
- Kala Pharmaceuticals, Inc.
- Sellers
- Kala Pharmaceuticals, Inc.
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Transaction Type
- Divestiture
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.